Filing Details
- Accession Number:
- 0000905148-20-001037
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-09-22 17:21:21
- Reporting Period:
- 2020-09-18
- Accepted Time:
- 2020-09-22 17:21:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1634379 | Metacrine Inc. | MTCR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1278411 | S Corey Goodman | 1700 Owens Street Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1504130 | Venbio Global Strategic Fund, L.p. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1770834 | Venbio Global Strategic Gp, L.p. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | No | No | |
| 1770835 | Venbio Global Strategic Gp, Ltd. | 1700 Owens Street, Suite 595 San Francisco CA 94158 | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2020-09-18 | 230,000 | $13.00 | 230,000 | No | 4 | P | Direct | |
| Common Stock | Acquisiton | 2020-09-18 | 2,829,123 | $0.00 | 3,059,123 | No | 4 | C | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Direct | |
| No | 4 | C | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Convertible Preferred Stock | Disposition | 2020-09-18 | 1,960,784 | $0.00 | 1,960,784 | $0.00 |
| Common Stock | Series B Convertible Preferred Stock | Disposition | 2020-09-18 | 472,250 | $0.00 | 472,250 | $0.00 |
| Common Stock | Series C Convertible Preferred Stock | Disposition | 2020-09-18 | 396,089 | $0.00 | 396,089 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct | ||
| 0 | No | 4 | C | Direct |
Footnotes
- Every 5.1 shares of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into one share Common Stock upon the closing of the Issuer's initial public offering. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.
- The shares are held by venBio Global Strategic Fund, L.P. venBio Global Strategic GP, L.P. is the general partner of venBio Global Strategic Fund, L.P. and venBio Global Strategic GP, Ltd. is the general partner of venBio Global Strategic GP, L.P. Corey Goodman is a director of venBio Global Strategic GP, Ltd. Each of venBio Global Strategic GP, L.P., venBio Global Strategic GP, Ltd. and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Billionaire Hedge Funds
